Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma

• Heli Vajavaara,
• Frida Ekeblad,
• Harald Holte,
• Judit Jorgensen,
• Suvi-Katri Leivonen,
• Mattias Berglund,
• Peter Kamper,
• Holger J. Moller,
• Francesco d’Amore,
• Daniel Molin,
• Gunilla Enblad,
• Maja Ludvigsen,
• Ingrid Glimelius,
• Sirpa Leppa

Affiliations

Heli Vajavaara

Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki

Frida Ekeblad

Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala

Harald Holte

Department of Oncology and KG Jebsen center for B-cell malignancies, Oslo University Hospital, Oslo

Judit Jorgensen

Department of Hematology, Aarhus University Hospital, Aarhus

Suvi-Katri Leivonen

Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki

Mattias Berglund

Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala

Peter Kamper

Department of Hematology, Aarhus University Hospital, Aarhus

Holger J. Moller

Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus

Francesco d’Amore

Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus

Daniel Molin

Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala

Gunilla Enblad

Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala

Maja Ludvigsen

Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus

Ingrid Glimelius

Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Medicine, division of clinical epidemiology, Karolinska Institutet, Solna

Sirpa Leppa

Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki